Castleview Partners’s Idexx Laboratories IDXX Stock Holding History

Castleview Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-423	Closed	-$223K	–	226
2026 Q2	$223K	Buy	423 +3	+0.7%	+$1.68K	0.1%	197
2026 Q1	$236K	Sell	420 -85	-17%	-$54.5K	0.12%	176
2025 Q4	$342K	Buy	505 +4	+0.8%	+$2.72K	0.17%	125
2025 Q3	$320K	Hold	501	–	–	0.17%	123
2025 Q2	$269K	Buy	+501	New	+$240K	0.17%	140
2024 Q2	–	Sell	-69	Closed	-$37.3K	–	961
2024 Q1	$37.3K	Hold	69	–	–	0.02%	383
2023 Q4	$38.3K	Hold	69	–	–	0.03%	356
2023 Q3	$30.2K	Hold	69	–	–	0.03%	323
2023 Q2	$34.7K	Hold	69	–	–	0.03%	307
2023 Q1	$34.5K	Hold	69	–	–	0.03%	295
2022 Q4	$28.1K	Hold	69	–	–	0.03%	277
2022 Q3	$22K	Sell	69 -1,063	-94%	-$390K	0.02%	312
2022 Q2	$206K	Buy	1,132 +1,014	+859%	+$413K	0.16%	136
2022 Q1	$64K	Buy	+118	New	+$62.1K	0.04%	316
2021 Q2	$75K	Buy	+118	New	+$65.2K	0.03%	338

Other funds holding IDXX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Castleview Partners's IDXX Position: Q3 2026 in Review

Castleview Partners sold out of Idexx Laboratories (IDXX) in Q3 2026, closing a stake of 423 shares — an estimated $223K sold.

Castleview Partners first reported a position in IDXX in Q2 2021 and held it in 15 quarters. The position peaked at $342K in Q4 2025. 733 funds tracked by Wall St. Rank hold IDXX as of Q3 2026.

Castleview Partners reported no remaining Idexx Laboratories position as of Q3 2026 after selling out during the quarter.
Castleview Partners sold 423 Idexx Laboratories shares in Q3 2026, an estimated $223K.
Castleview Partners first reported a position in Idexx Laboratories in Q2 2021 and held it in 15 quarters.
Castleview Partners's Idexx Laboratories position peaked at $342K in Q4 2025.
733 funds tracked by Wall St. Rank held Idexx Laboratories as of Q3 2026.

Based on Castleview Partners's 13F filing for Q3 2026, filed 9 Oct 2026.